Optima Capital’s ADMA Biologics ADMA Stock Holding History

Optima Capital’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,000	Closed	-$36.5K	–	173
2025 Q4	$36.5K	Buy	+2,000	New	+$33.7K	0.02%	349

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Optima Capital's ADMA Position: Q1 2026 in Review

Optima Capital sold out of ADMA Biologics (ADMA) in Q1 2026, closing a stake of 2,000 shares — an estimated $36.5K sold.

Optima Capital first reported a position in ADMA in Q4 2025 and held it in 1 quarter. The position peaked at $36.5K in Q4 2025. 357 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

Optima Capital reported no remaining ADMA Biologics position as of Q1 2026 after selling out during the quarter.
Optima Capital sold 2,000 ADMA Biologics shares in Q1 2026, an estimated $36.5K.
Optima Capital first reported a position in ADMA Biologics in Q4 2025 and held it in 1 quarter.
Optima Capital's ADMA Biologics position peaked at $36.5K in Q4 2025.
357 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Optima Capital's 13F filing for Q1 2026, filed 5 May 2026.